Background. The long-term effectiveness of the quadrivalent human papillomavirus (qHPV) vaccine was assessed by monitoring the combined incidence of cervical intraepithelial neoplasia (CIN2, CIN3), adenocarcinoma in situ (AIS), and cervical cancer related to HPV16 or HPV18.
immunization with the qHPV vaccine through 9 years [12] , as well as immune memory and anamnestic immune responses [13] [14] [15] .
A long-term study of boys and girls aged 9-15 years demonstrated safety, effectiveness, and immunogenicity of the qHPV vaccine for more than 8 years [16] . Our objective in this study was to assess the long-term effectiveness of qHPV vaccine by monitoring the combined incidence of cervical intraepithelial neoplasia (CIN2, CIN3, adenocarcinoma in situ (AIS), and cervical cancer related to HPV type16 or HPV type18 in Nordic women vaccinated with the qHPV vaccine at age 16-23 years and followed for up to 14 years post-vaccination. As a secondary objective, we also assessed the long-term effectiveness of the qHPV vaccine against vulvar and vaginal cancer.
MATERIAL AND METHODS

Base Study
The base study (Females United to Unilaterally Reduce Endo/ Ectocervical Disease [FUTURE] II) was a randomized, double-blind, placebo-controlled clinical trial that enrolled 12 167 women from 13 countries covering 4 continents [5] . Women who were not pregnant, had no abnormal Pap tests, and had a lifetime number of no more than 4 sexual partners were eligible for enrollment in the base study. An institutional review board for each respective study site approved the protocol, and written informed consent was obtained from all participants. Participants were followed for a median time of 4 years in the base study.
Long-Term Follow-up Study
The long-term follow-up (LTFU) study is an ongoing 10-year extension of the 4-year base study in the Nordic countries (Denmark, Norway, Sweden, and Iceland). This study originally included 5492 women in Denmark, Iceland, Norway, and Sweden, randomized in a 1:1 ratio and who received either qHPV vaccine or placebo in the base study. Participants in the placebo arm of the base study were offered the qHPV vaccine at the end of the base study. All participants from the base study who consented for effectiveness follow-up (97%) were included in the overall LTFU. In the current study, only women who received the qHPV vaccine in the base study (n = 2650) were included. The effectiveness analysis is based on the per-protocol effectiveness (PPE) population (N = 2195), excluding 455 women who did not fulfill the PPE criteria as defined in the original and subsequent analyses of FUTURE II. The criteria included being seronegative and HPV DNA polymerase chain reaction (PCR)-negative at baseline (ie, start of FUTURE II) and PCR-negative through month 7 to the relevant HPV type(s), received 3 doses of qHPV vaccine within 1 year, did not violate the protocol, and consented to effectiveness follow-up.
Follow-up
Every citizen in the Nordic countries is assigned a unique personal identification number (PIN) at birth or at immigration, which is registered in the civil registration system in each country. Due to the existence of these PINs and the nationwide health registries, which contain personalized health-related data, it is possible to do follow-up studies with virtually no loss to follow-up.
Using the PIN as the key identifier, all women were followed through linkages with different nationwide registries for cervical, vulvar, and vaginal abnormalities in the respective countries up to 1 March 2013. The LTFU study started immediately upon the end of FUTURE II, and analyses were performed in 2-year intervals following completion of FUTURE II (Figure 1 ). Women in this LTFU study were aged 16-23 years upon enrollment into the base study and will have been followed for a total of 14 years after initial vaccination in the FUTURE II trial until approximately 30-37 years of age. This will cover the age of peak incidence of HPV-16/18-related CIN2+.
Effectiveness Endpoints
Hematoxylin and eosin (H&E)-stained slides and formalin-fixed paraffin-embedded tissue blocks were used for pathology diagnosis. Following the registry-based identification of all cases of CIN2, CIN3, AIS, cervical cancer, vulvar cancer, and vaginal cancer, these blocks were retrieved from the relevant pathology departments in each country. Tissue sections were cut for thin-section PCR testing for 14 HPV types (6, 11, 16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, and 59) [5, 17] , and new H&E-stained slides were created. For pathology diagnosis, H&E slides obtained from pathology laboratories and new slides were evaluated together by the Nordic Pathology Panel (NPP). The NPP, which included 1 pathologist from each of the 4 participating countries, was summoned for the LTFU study. The NPP was blinded for histology diagnosis (local and NPP) and reviewed all biopsy slides for a consensus diagnosis (agreement by at least 2 pathologists). Further, all tissue samples were tested for HPV 6, 11, 16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, and 59 using the PCR testing method used in the base study [5] . Vaccine effectiveness against, for example, HPV16/18-related CIN2+ was estimated by comparing the observed incidence with the expected incidence of CIN2+ in an unvaccinated cohort using historical registry data. Information from Nordic registries prior to introduction of the vaccine accurately measured the incidence of HPV-related disease in the entire population in an unvaccinated state. In addition, a questionnaire study (the Concomitant Cohort Study), which included nearly 70 000 women from the 4 Nordic countries, was performed prior to introduction of HPV vaccination (2004) (2005) [18] . In this study, information on lifestyle, including sexual habits, was obtained from all participants. Combining these 2 data sources and taking into account the proportions of participants in the LTFU study from Denmark, Iceland, Norway, and Sweden, the incidence of HPV-related CIN2+ among participants aged 23-29 years with 1 to 6 sexual partners in the Concomitant Cohort Study was 5.22/1000 person-years. Because approximately 55% of the HPV-related CIN2+ lesions in the population data are related to HPV16 or 18 [17, [19] [20] [21] , the incidence of HPV16/18-related CIN2+ was assumed to be 0.287/100 person-years in unvaccinated women.
Statistical Methods
To monitor the long-term effectiveness of GARDASIL™ with respect to HPV16/18-related CIN2/3 and cervical cancer, an adapted 1-sided Shewhart control chart was developed and implemented. The chart is an adapted version of the 1-sided Poisson Shewhart control chart, or c chart, and is designed to monitor the incidence rate of HPV16/18-related CIN 2+ in the Nordic LTFU study participants over a 12-year period. Adaptation was necessary so that incidence rates and vaccine effectiveness could be calculated and plotted specific to time since vaccination.
In order to use a c chart in this application, 2 adjustments were made to the standard 1-sided c chart so that it could be used to monitor vaccine effectiveness. First, the center line (CL) and upper control limit (UCL) were adjusted for each time interval in each analysis to account for differing amounts of follow-up time, which changes the expected disease incidence count and the variance in each interval of the chart. In addition, the disease incidence estimates in each time interval were updated each time a new analysis was conducted as more data became available. These changes were incorporated into the standard 1-sided c chart by letting t represent the total number of time intervals on the control chart and letting s represent the total number of analyses conducted. Then, the CL and UCL were calculated using the following formulas:
where, i = 1, 2, …, t and j = 1, 2, …, s. The true disease incidence count for time interval i and analysis s, X ij , is assumed to follow a Poisson distribution with mean c ij then x ij represents the disease incidence estimate plotted for the ith interval in the jth analysis. The constant, k, represents the number of standard deviations the UCL is above the center line.
To apply the adapted 1-sided c chart in the Nordic LTFU study, the baseline rate was assumed to be 0.0287/100 person-years in vaccinees, which corresponds to 90% effectiveness based on the estimated historical rate of HPV16/18-related CIN2+ of 0.287/100 person-years in unvaccinated women. This was used to detect any decrease in vaccine effectiveness below 90%. Five control chart analyses will be conducted over the 10-year period of the study, 1 every 2 years, where the width of the time intervals on the control charts are 2 years based on the expected visit schedule; the intervals begin at year 4 following vaccination. The adapted 1-sided c chart signals if any point, x ij , crosses a UCL with k = 3 or if 2 out of 3 consecutive points cross a UCL with k = 2. Such a signal indicates that the incidence rate may have increased relative to the baseline rate or, equivalently, that vaccine effectiveness of at least 90% may not have been maintained. In addition, there is potential for false-positive and false-negative signals on the control charts due to lack of follow-up time within an individual interval. Therefore, points were not plotted when there was less than 60% of the total expected follow-up time in an interval [22] . Table 1 shows the results of the analysis of effectiveness against HPV16/18-related CIN2 or worse among women who received the qHPV vaccine at the start of the base study. There were 2084 evaluable participants, contributing 13794.9 person-years of follow-up since day 1 of the base study out of the 2195 eligible participants in the PPE population; 111 women were lost to follow-up because they had no follow-up visit in the LTFU study or they emigrated during the study period.
RESULTS
There were no observed cases of HPV16/18-related CIN2+. The estimated baseline incidence rate of HPV16/18-related CIN2+ in this vaccinated cohort would have been 0.0287/100 person-years if vaccine efficacy was maintained at 90%. Based on the 13794.9 person-years of follow-up time accrued, 3 cases were expected if vaccine efficacy was maintained at 90%. Based on the number of eligible participants in this population, a minimum of 2634 person-years of follow-up time is necessary in any given interval of time since year 4 in order to draw firm conclusions from the results of this analysis based on the statistical method. A total of 3393.1 person-years have now been accrued over the period from 8 to 10 years following vaccination, which is a sufficient amount of follow-up time to conclude that the qHPV vaccine continued to be effective beyond the initial follow-up period of the base study to at least 10 years post-vaccination. The same pattern was seen in the interval up to 12 years; however, it must be noted that although effectiveness appears to be maintained up to 10 years, there is insufficient follow-up time in the 10-12 year interval to make a conclusive claim of effectiveness beyond 10 years at this time. There was sufficient statistical power to assess a continued effectiveness by HPV type and by type of lesion, as shown in Table 1 . The control chart for effectiveness of HPV16/18-related CIN2 or worse in the PPE population is shown in Figure 2 . As shown in the graph, evaluation of vaccine effectiveness in this analysis begins at year 4 post-vaccination. The points on the plot indicate the number of cases observed in each 2-year interval starting from year 4. Shaded intervals indicate time periods where too few person-years have been observed to make an assessment. In the unshaded intervals, if 1 point crosses the 3-sigma control limit or 2 out of 3 points cross the 2-sigma control limit, this indicates that vaccine effectiveness may have drifted below 90%. No points have crossed the 2-or 3-sigma limits in the evaluable period from 8 to 10 years post-vaccination. Thus, we observed no signals indicating a decrease in vaccine effectiveness for at least 10 years in the PPE population. Table 2 shows the vaccine effectiveness against HPV 6/11/16/18-related CIN, vulvar cancer, and vaginal cancer among women who received qHPV vaccine at the start of baseline study, in the PPE population. There was 1 case of CIN1 observed in the 6-to 8-year period. The person-years at risk for this population was 15242.4, resulting in a disease incidence of 0.0 (95% confidence interval, 0.0, 0.1) per 100 person-years at risk. These results are consistent with the PPE primary endpoint results (ie, effectiveness related to CIN2+), providing further support that vaccine effectiveness has been maintained beyond the initial base study to at least 10 years post-vaccination.
The single case of CIN1 in this cohort was from a 31-yearold woman with unknown past medical history who was vaccinated with qHPV in the base study at age 20 years. At study entry, she was negative by PCR and serology for HPV6, 11, 16, and 18 but positive by PCR for HPV45 and 51. The CIN1 lesion developed during the course of follow-up. HPV16, 45, and 52 were identified from the CIN1 lesion via PCR during follow-up. Type 16 was identified for the first time from the CIN1 lesion only (and not at baseline). It is unlikely to be the HPV type that produced the lesion because of the duration of the presence of type 45 and because HPV16 was detected only once.
She underwent cone excision for a cervical lesion 6 years later. Her specimens had portions of AIS as well as CIN1, and the margins were noted to be negative for any disease. The AIS lesions in her specimens were found to be PCR positive primarily for HPV45, and a new presence of HPV52 was also noted. She appeared to have both CIN1 and AIS related to longstanding infection with HPV45. Additionally, she was classified as having CIN1 cervical disease related to HPV16. A follow-up Pap smear was normal and negative for HPV.
DISCUSSION
We found no breakthrough cases of HPV16/18-related CIN2 or worse in this study up to more than 12 years following vaccination of women aged 16-23 years with the qHPV vaccine. The accumulated person-time through 10 years of follow-up was sufficient to achieve statistical confidence that effectiveness remains at least above 90%. The women who initially received the qHPV vaccine in the clinical trial were vaccinated at least 4 years prior to those who received placebo. Thus, it is reassuring to see no sign of breakthrough cases in the present analysis. We recently reported that the anti-HPV geometric mean titers and the proportion of seropositive individuals remained high up to 9 years post-vaccination among women who received the qHPV vaccine in the base study [12] . There was one case of HPV16-related CIN1, but no cases of vulvar or vaginal cancer. It is difficult to interpret the significance of the observed single CIN1 lesion that was positive for HPV16. The persistence and duration of HPV45 infection and associated disease in this participant points to HPV45 as the likely etiologic agent causing both the AIS and CIN1. As noted previously, a follow-up Pap smear following cone excision was normal and negative for HPV. This study is unique and is only feasible because of the existence of the PINs used universally in society and the high-quality nationwide registries in the countries involved in this research. This secures an accurate linkage between registries and implies that registry-based follow-up studies can be conducted in the Nordic countries with virtually no loss to follow-up. Vaccine effectiveness can continue to be monitored for years while study participants go about their daily lives and see their healthcare providers. The likelihood of missing cases of disease is very low because cervical cancer screening is an established program in each country and women receive reminder letters if a screening appointment is missed. Taken together, the Nordic registries have high completeness, which implies that case ascertainment is very high in the current study.
In conclusion, in this long-term follow-up study we found that the qHPV vaccine is effective against HPV16/18 CIN2+ through at least 10 years after vaccination of women aged 16-23 years with a trend toward 12 years of protection. These results are important because they suggest that there is no need for an additional dose of the qHPV vaccine in order to achieve longterm effectiveness after the 3-dose regimen in young women. Despite the effectiveness of the vaccine, vaccinated women will need to continue to attend screening for cervical cancer. Future reports will assess effectiveness during a follow-up period of up to 14 years or more. Financial support. The study was sponsored and funded by Merck & Co., Inc., which manufactures the quadrivalent and nonvalent HPV vaccines under the brand names GARDASIL™ and GARDASIL-9™. The study was designed, managed, and analyzed by the sponsor in conjunction with external investigators. As the study sponsor, Merck & Co., Inc. was directly involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation and review of the manuscript. Authors had access to all study data upon request. The lead (S. K. K.) and senior (A. J. S.) authors had full access to all results from the study and assume responsibility for the integrity of the data and the accuracy of the data analyses. A final version of the paper was approved by each coauthor. The presentation also underwent formal review by the sponsor.
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